GMV reached a new quarterly high of $1.2 billion in 4Q25, representing a 35.3% YoY increaseTotal Revenue jumped 32.2% YoY to $129.9 million for 4Q25Net Income Per Diluted Share1 and Adjusted Net Income per Diluted Share1, 2 reached $1.21 in the fourth quarter, representing 72.9% and 68.1% YoY increases, respectivelyFor full-year 2025, Total Revenue grew 66.1% YoY to $450.3 millionNet Income for FY2025 jumped 69.5% YoY to $133.1 million, or $3.72 per diluted share1Full-year Adjusted Net Income2 increased 96. ...

LOUISVILLE, Ky., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (Nasdaq: CHDN) (the "Company", "CDI", "we") today reported business results for the quarter and full year ended December 31, 2025. Company Highlights Fourth quarter 2025 financial results, as compared to the prior year quarter: Record net revenue $665.9 million, up $41.7 million or 7%Net income attributable to CDI of $51.3 million, down $20.4 million or 28%Record Adjusted EBITDA of $247.0 million, up $10.4 million or 4% On Septe ...

REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the th ...

Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, I ...

Highlights (All comparisons are to the prior year period unless otherwise noted): Fourth Quarter Net sales of $537.9 million, up 0.8%Diluted earnings per share (“EPS”) of $0.38, down 79%, reflecting a $51.1 million non-cash goodwill impairment charge related to the Heavy Duty segmentAdjusted diluted EPS* of $2.17, down 1%Generated $41.6 million of cash from operating activities Full Year Net sales of $2.13 billion, up 6.0%Diluted EPS of $6.64, up 8%, inclusive of a $51.1 million non-cash goodwill impairment ...

DALLAS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, is pleased to announce that its Board of Directors has declared monthly regular dividends of $0.1934 per share for each of April, May and June 2026 and a quarterly supplemental dividend of $0.06 per share payable in J ...

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day o ...

LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the ...

MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen 46th Annual Healthcare Conference at 10:30 a.m. ET on Wednesday, March 4, 2026. A live webcast will be available us ...

Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin expansion ...